Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Authors:
- Brian G. FeaganBFBrian G. Feagan
- Gordon R. GreenbergGGGordon R. Greenberg
- Gary WildGWGary Wild
- Richard N. FedorakRFRichard N. Fedorak
- Pierre ParéPPPierre Paré
- John W.D. McDonaldJMJohn W.D. McDonald
- Albert CohenACAlbert Cohen
- Alain BittonABAlain Bitton
- Jeffrey BakerJBJeffrey Baker
- Réjean DubéRDRéjean Dubé
- Steven B. LandauSLSteven B. Landau
- Margaret K. VandervoortMVMargaret K. Vandervoort
- 1 December 2008
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 6 (12) , 1370-1377
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Review article: appropriate use of corticosteroids in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2007
- Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE TrialGastroenterology, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I TrialGastroenterology, 2006
- The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agentsCritical Reviews in Oncology/Hematology, 2005
- A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s DiseaseGastroenterology, 2005
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Immunomodulator therapy in inflammatory bowel diseaseDigestive Diseases and Sciences, 1994
- Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.Gut, 1993